1,2,3,4-Tetrakis(bromomethyl)naphthalene

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2,3,4-Tetrakis(bromomethyl)naphthalene
• 化学式: C₁₄H₁₂Br₄
• 分子量: 499.9
• InChiKey: RGMRKCCPGPIVKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• Detection of cleavage activity of an enzyme
  申请人：Mologic Limited

  公开号：US10866236B2

  公开（公告）日：2020-12-15

  The present invention relates to detecting cleavage activity of an enzyme. The various aspects of the invention include an enzyme detection device, kit, method and use for detecting or measuring the presence in a test sample of the activity of an enzyme capable of cleaving a substrate. The invention also relates to indicator and binding molecules useful for carrying out the invention. The enzyme substrate contains a hidden binding site which is only revealed upon cleavage by the enzyme.

  本发明涉及检测酶的裂解活性。本发明的各个方面包括一种酶检测装置、试剂盒、方法和用途，用于检测或测量检测样品中是否存在能够裂解底物的酶的活性。本发明还涉及用于实施本发明的指示剂和结合分子。酶底物含有一个隐藏的结合位点，只有在被酶裂解时才会显示出来。
• DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME
  申请人：Mologic Limited

  公开号：EP3060915B1

  公开（公告）日：2018-12-05
• MONITORING INFLAMMATION STATUS
  申请人：Mologic Limited

  公开号：EP3111226B1

  公开（公告）日：2019-05-01
• Detection of Cleavage Activity Of An Enzyme
  申请人：MOLOGIC LIMITED

  公开号：US20160238596A1

  公开（公告）日：2016-08-18

  The present invention relates to detecting cleavage activity of an enzyme. The various aspects of the invention include an enzyme detection device, kit, method and use for detecting or measuring the presence in a test sample of the activity of an enzyme capable of cleaving a substrate. The invention also relates to indicator and binding molecules useful for carrying out the invention. The enzyme substrate contains a hidden binding site which is only revealed upon cleavage by the enzyme.
• Monitoring Inflammation Status
  申请人：Mologic Limited

  公开号：US20170108511A1

  公开（公告）日：2017-04-20

  Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.